Research Article

Endothelin-1 Downregulates Sulfur Dioxide/Aspartate Aminotransferase Pathway via Reactive Oxygen Species to Promote the Proliferation and Migration of Vascular Smooth Muscle Cells

Xiaoyu Tian,1,2 Qingyou Zhang,1 Yaqian Huang,1 Selena Chen,3 Chaoshu Tang,4,5 Yan Sun,1 Junbao Du,1 and Hongfang Jin1

1Department of Pediatrics, Peking University First Hospital, Beijing 100034, China
2Research Unit of Clinical Diagnosis and Treatment of Pediatric Syncope and Cardiovascular Diseases, Chinese Academy of Medical Sciences, Beijing, China
3Division of Biological Sciences, University of California, La Jolla, San Diego, California 92093, USA
4Key Laboratory of Molecular Cardiology, Ministry of Education, Beijing, China
5Department of Physiology and Pathophysiology, Peking University Health Science Centre, Beijing 100091, China

Correspondence should be addressed to Junbao Du; junbaodu1@126.com and Hongfang Jin; jinhongfang51@126.com

Received 22 March 2019; Accepted 6 January 2020; Published 29 January 2020

Academic Editor: Victor M. Victor

Copyright © 2020 Xiaoyu Tian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The regulatory mechanisms for proliferation and migration of vascular smooth muscle cells have not yet been clear. The present study was designed to investigate whether and how endothelin-1 (ET-1) impacted the generation of endogenous sulfur dioxide (SO2) in rat vascular smooth muscle cells (VSMCs) proliferation and migration. Primary VSMCs and purified aspartate aminotransferase (AAT) protein were used in this study. We found that in the presence of ET-1, the expression of PCNA and Ki-67 was upregulated and the migration of VSMCs was promoted, while the AAT activity and SO2 levels in VSMCs were reduced without any changes in AAT1 and AAT2 expression. SO2 supplementation successfully prevented the ET-1-facilitated expression of PCNA and Ki-67 and the migration of VSMCs. Interestingly, ET-1 significantly increased reactive oxygen species (ROS) production in association with SO2/AAT pathway downregulation in VSMCs compared with controls, while the ROS scavenger N-acetyl-L-cysteine (NAC) and the antioxidant glutathione (GSH) significantly abolished the ET-1-stimulated downregulation of the SO2/AAT pathway. Moreover, the AAT activity was reduced in purified protein after the treatment for 2 h. However, NAC and GSH blocked the hydrogen peroxide-induced AAT activity reduction. In conclusion, our results suggest that ET-1 results in the downregulation of the endogenous SO2/AAT pathway via ROS generation to enhance the proliferation and migration of VSMCs.

1. Introduction

The proliferation and migration of vascular smooth muscle cells are the pathophysiological basis of many cardiovascular diseases. A variety of factors are involved in these processes, such as gasotransmitters and vasoactive peptides. The impacts of small vasoactive molecules on vascular proliferation, migration, and remodeling depend on the integrated effects of the molecules [1, 2]. Therefore, it is of great scientific significance to explore the interactions between gasotransmitters and vasoactive peptides and the regulatory mechanisms for vasoactive molecules to understand the possible mechanism underlying vascular smooth muscle cell (VSMC) proliferation and migration.

Endothelin-1 (ET-1) is a plasma protein secreted by vascular endothelial cells that possesses potent vasoconstrictive activity [3]. It induces biological or pathological effects upon binding to the ETA receptor in VSMCs [4]. Previous studies
have demonstrated that ET-1 levels are increased in many cardiovascular diseases, such as salt-sensitive hypertension [5] and atherosclerosis [6]. Simultaneously, the proliferation and migration of VSMCs are involved in the development of cardiovascular diseases.

In previous studies, sulfur dioxide (SO₂) was regarded as an environmental pollutant [7]. In recent years, it was found that the SO₂ pathway was endogenously generated in cardiovascular tissues. SO₂ is produced during the metabolism of sulfur-containing amino acids and catalyzed by aspartate aminotransferase 1 (AAT1) and aspartate aminotransferase 2 (AAT2) [8]. At a low concentration, SO₂ has a variety of physical functions, such as vasodilation and lipid regulation [9]. Animal studies have shown that ET-1 secretion is significantly increased and the SO₂ content in the serum declines in spontaneously hypertensive rats (SHR) [10, 11]. Recent studies have indicated that ET-1 concentrations are elevated in the lung tissue but SO₂ levels are decreased in rats with hypoxia-induced pulmonary hypertension [12]. Earlier studies revealed that there were decreased plasma SO₂ levels and aortic SO₂ production but increased endothelial ET-1 levels in atherosclerosis [13, 14]. The results indicated that there might be an interaction between ET-1 and SO₂ in cardiovascular diseases. However, the impact of ET-1 on the endogenous SO₂ pathway and the subsequent effects on the proliferation and migration of vascular smooth muscle cells remain unclear.

Reactive oxygen species (ROS) are by-products of normal oxygen metabolism [15]. They are atoms or molecules that possess one or more unpaired electrons in the outer orbit, including the hydroxyl radical (OH), hydrogen peroxide (H₂O₂), superoxide anion (O₂⁻) and peroxynitrite (ONOO⁻) [16]. It has been known for years that vascular and cardiac tissues are rich sources of ROS, and smooth muscle cells and fibroblasts produce the majority of O₂⁻ found in the normal vessel wall [17]. ROS are implicated in the pathogenesis of vascular injury diseases [18]. It was reported that plasma ET-1 levels were significantly increased in patients with pulmonary hypertension and that increased ET-1 binding to smooth muscle cell receptors resulted in persistent elevation of ROS levels, further aggravating vascular damage [19]. A recent report suggested that pulmonary remodeling was associated with increased ROS production in a lamb pulmonary hypertension model induced by catheter ligation [20]. ROS within cells act as secondary messengers in intracellular signaling cascades, and SO₂ is highly affected by the redox state in vivo [21]. Therefore, the present study was undertaken to examine whether ET-1 regulates the generation of endogenous SO₂ in VSMCs, affecting the proliferation and migration of VSMCs and the possible mechanisms associated with ROS production.

2. Materials and Methods

2.1. Cell Culture and Grouping. In cell experiments in vitro, primary VSMCs were harvested from male Wistar rats (Vital River, Beijing, China) weighing 180-200 g. The thoracic aorta was stripped of the adventitia and aseptically transferred into culture medium. Primary VSMCs were isolated and cultured according to the method used by Chi et al. [22]. The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, USA) supplemented with 10% FBS in an atmosphere of 5% CO₂ at 37°C. The media were changed to serum-free DMEM for 24 h when the VSMCs were grown to 70%-80% confluence. This study was approved by the Animal Ethics Committee of Peking University First Hospital (EC Approval No. J 201858) and was conducted in strict accordance with applicable regulations of the Animal Ethics Committee of Peking University.

Cells were divided into the control and experimental groups. ET-1 at a concentration of 10⁻⁸ M, 10⁻⁷ M, and 10⁻⁶ M was added to the experimental group as previously described [23–26], and for the control group, the same volume of a sterile PBS buffer solution was added. To assess the effects on the proliferation and migration of VSMCs, cells were divided into the following groups: control group, 10⁻⁶ M ET-1 group, 100 μM SO₂ group, and ET-1+SO₂ group.

To investigate the effects of ET-1 on the endogenous SO₂ pathway and its mechanisms in VSMCs, cells were divided into the following groups: control group, 10⁻⁶ M ET-1 group, N-acetyl-L-cysteine (NAC) group, NAC+10⁻⁶ M ET-1 group, glutathione (GSH) group, and GSH+10⁻⁴ M ET-1 group. The concentrations of NAC and GSH were 5 mM and 10 mM, respectively. In purified protein experiments, purified AAT protein was divided into the control group, 200 μM H₂O₂ group, 200 μM H₂O₂+5 mM NAC group, and 200 μM H₂O₂+10 mM GSH group.

2.2. In Situ Fluorescence Measurement of SO₂. Endogenous SO₂ in primary VSMCs was observed using a fluorescent probe (provided by Professor Kun Li and Xiaoqi Yu, Sichuan University, Sichuan, China) [27]. After drug stimulation for 48 h, an SO₂ fluorescent probe working fluid (10 μM) was added to the medium of cells and incubated for 30 min at 37°C. The cells were washed 3 times with 0.01 M PBS. The cells were fixed in 4% paraformaldehyde for 15 to 20 min at room temperature and rinsed 3 times in 0.01 M PBS for 5 min each time. The cells were detected as blue fluorescence by confocal microscopy.

2.3. Western Blotting. Primary VSMCs were seeded into 6-well plates. After drug treatment for 48 h, cell extracts were resolved on an SDS polyacrylamide gel and blotted on NC membranes. Nonspecific binding was blocked by an incubation in a 5% milk blocking buffer. The NC membranes were incubated overnight at 4°C with the following primary antibodies: anti-AAT1 (1:1000; Sigma-Aldrich, USA), anti-AAT2 (1:1000; Sigma-Aldrich, USA); anti-PCNA (1:1000, Anbo Biotechnology, USA), anti-Ki-67 (1:500; Zhongshan Jinqiao, China), and anti-GAPDH (1:4000; Shanghai Kangcheng, China). The membranes were then washed and hybridized for 1 h at room temperature with the following secondary antibodies: HRP-conjugated goat anti-rabbit (Cell Signaling Technology, USA), HRP-conjugated goat anti-mouse (Cell Signaling Technology, USA), and HRP-conjugated rabbit anti-goat (Santa Cruz, USA). Immunoreactions were visualized using an enhanced chemiluminescence detection kit.
2.4. Cell Scratch-Wound Assay. Primary VSMCs were seeded into a cell migration chamber (IBIDI, Germany). After the cells adhered to the chamber, the medium was replaced with serum-free medium for 24 h to synchronize the cells. Then, the migration chamber was removed, and the length of the cell scratch was immediately photographed under a microscope. Then, 100 μM SO2 and 10^-6 M ET-1 were added to the medium, and cell migration was determined again at 48 h.

2.5. AAT Activity Analysis. After drug stimulation for 48 h, primary VSMCs were harvested and lysed in PBS. A portion of the isolated protein was used to detect the protein concentration by Bradford’s method, and the remaining protein was used to detect AAT activity. AAT activity was tested by using an AAT activity microplate test kit (Nanjing Jiancheng Bioengineering Institute, China) according to the manufacturer’s instructions.

2.6. Determination of ROS. Cells were seeded into 8-well chambers and allowed to adhere for at least 24 h. The cells were grown to 60%-70% confluence and allowed to adhere for at least 24 h. The cells were seeded into 8-well chambers and allowed to adhere for at least 24 h. The cells were then washed with PBS 3 times. DHE-stained cells were observed as red fluorescence by confocal microscopy. The average fluorescence intensities were quantified using Image J.

2.7. Data Analysis. Data were expressed as mean ± SEM, and data analysis was performed with SPSS 20.0 software. When the data were normally distributed, comparisons among multiple groups were made by one-way ANOVA followed by the LSD test for post hoc comparisons as appropriate. Otherwise, Dunnett’s T3(3) test was used for comparisons. P < 0.05 was considered significant.

3. Results

3.1. ET-1 Downregulates the SO2/AAT Pathway in Primary VSMCs. Cultured primary VSMCs were treated with different concentrations of ET-1 (10^-8, 10^-7, or 10^-6 M) for 48 h. We found that compared with that of the control, the fluorescence signal for the SO2 content of the treated VSMCs gradually weakened (all P < 0.05) in the 10^-8, 10^-7, and 10^-6 M ET-1 groups (Figure 1(a)).

Next, we determined whether AAT activity and expression were affected by ET-1. There was no significant difference (all P > 0.05) in the primary VSMC expression of AAT between the control VSMCs and VSMCs treated with different concentrations of ET-1 (10^-8, 10^-7, or 10^-6 M) (Figures 1(b) and 1(c)). However, the AAT enzyme activity was notably reduced (all P < 0.05), respectively, in all the cells treated with ET-1 (10^-8 M, 10^-7 M, and 10^-6 M) compared with the controls (Figure 1(d)).

3.2. Supplementation with SO2 Abolished ET-1-Induced VSMC Proliferation and Migration. The results showed that compared with the control group, the 10^-6 M ET-1 group exhibited significantly enhanced expression of PCNA and Ki-67 (P < 0.05, Figures 2(a) and 2(b)) and a narrower wound width (P < 0.01, Figure 2(c)). However, pretreatment of the cells with 100 μM SO2 successfully abolished the increased PCNA and Ki-67 protein expression and cell migration induced by ET-1 in primary VSMCs.

3.3. Involvement of ROS in the ET-1-Induced Reduction in the SO2/AAT Pathway. To gain insight into the mechanisms by which ET-1 reduces endogenous SO2 generation, we detected the intracellular ROS and SO2 levels and AAT activity in primary VSMCs. As expected, compared with the controls, in the 10^-6 M ET-1-treated cells, the red fluorescence signal intensity indicative of ROS in primary VSMCs was markedly increased (P < 0.05), whereas the level of SO2 and AAT activity was decreased (P < 0.05, Figures 3(a)-3(e)). The presence of the ROS scavenger NAC successfully abolished the downregulation of the SO2 level and the reduced AAT activity associated with the ROS elevation. Similarly, pretreatment with another antioxidant, GSH, also significantly abrogated the ET-1-induced reduction in the SO2 content and the reduced AAT activity associated with the ROS augmentation (Figures 3(a)-3(e)).

To further confirm the direct effect of ROS on AAT activity, we measured the AAT activity of purified AAT protein. The data showed that AAT activity was significantly reduced (P < 0.01) in the presence of 200 μM H2O2 compared with control treatment. In the presence of 5 mM NAC and 10 mM GSH, the H2O2-induced reduction in the AAT activity of purified AAT protein was blocked (P < 0.01, Figure 3(f)).

4. Discussion

In the present study, we detected changes in the VSMC-derived SO2 production induced by ET-1. We found that ET-1 reduced SO2 generation by decreasing the activity of AAT without influencing AAT1 and AAT2 expression and that the ET-1-mediated reduction in the SO2 level participated in the excessive proliferation and migration of VSMCs (Figure 4).

We further explored the molecular mechanisms by which ET-1 triggers a reduction in AAT activity. In recent years, it has been shown that ROS acts as a secondary messenger and participates in multiple signal transduction pathways in cells to exert biological effects. ROS plays a major role in the pathogenesis of various cardiovascular diseases, including hypertension and atherosclerosis [28]. Most of these studies showed a possible relationship between ET-1 ROS and cardiac hypertrophy [29]. There was also evidence of a relationship among ET-1, ROS and VSMCs. In a study investigating pulmonary hypertension, plasma ET-1 levels were significantly elevated, and the increased ET-1 level was associated with an elevation in the ROS level [30]. ET-1 increases ROS production in VSMCs and functions as a critical mediator in ET-1-induced signaling events in association with growth-promoting proliferative and hypertrophic pathways in VSMCs [31]. In previous studies, some mechanisms were reported to be involved in the effects of ET-1 on ROS generation. Touyz et al. found that the mitochondrial
Figure 1: ET-1 downregulated the SO₂/AAT pathway in primary VSMCs. In situ fluorescent staining (blue) detection of endogenous SO₂ in primary VSMCs and quantified average fluorescence intensity by Image J. Fluorescent signal intensity reflects SO₂ levels (a). Protein expression of AAT1 and AAT2 in primary VSMCs (b, c). AAT activity in VSMCs (d). Results are expressed as mean ± SEM (n = 3-6). *P < 0.05, **P < 0.01 vs. control. AAT1: aspartate aminotransferase 1; AAT2: aspartate aminotransferase 2; ET-1: endothelin-1; VSMCs: vascular smooth muscle cells.
inhibitor, but not the NADPH oxidase inhibitor, attenuated the ET-1-induced ROS generation and the subsequent MAPK pathway activation in human vascular smooth muscle cells, suggesting that mitochondria might be an important source of ET-1-induced ROS [23], while it was found that ET-1 activated NADPH oxidase subunit Nox5 and therefore induced \( \text{O}_2^- \) generation in human endothelial cells [32]. Moreover, xanthine oxidase was also found to be involved in the ET-1-induced generation of ROS in the aorta and resistance arteries in rats [33]. Furthermore, the ET\(_A\) receptor not the ET\(_B\) receptor was found to be coupled to \( \text{O}_2^- \) and \( \text{H}_2\text{O}_2 \) production induced by ET-1 in pulmonary vascular smooth muscle cells [34, 35] or in cardiac fibroblasts [36], while the ET\(_B\) receptor antagonist prevented the ET-1-enhanced ROS generation in human umbilical vein endothelial cells [37]. \( \text{SO}_2 \) is a gasotransmitter that is highly sensitive to oxidative damage and is vulnerable to the steady-state changes of redox reactions. Therefore, we further explored whether ROS was the key link to the reduction in \( \text{SO}_2 \) content and AAT activity induced by ET-1.

Our present study showed that ET-1 could induce a reduction in \( \text{SO}_2 \) generation associated with ROS level elevation in VSMCs, and this effect was abolished by the oxidative stress scavenger NAC and the antioxidant GSH, demonstrating that NAC and GSH can mediate a reversal of the reductions in \( \text{SO}_2 \) content and AAT activity induced by ET-1. To
Figure 3: Continued.
Figure 3: Continued.
further study the direct role of ROS in AAT activity, purified AAT protein was stimulated with H$_2$O$_2$, and we found that ROS lowered the activity of AAT, but NAC and GSH abrogated this effect. The results indicated that ROS was involved in the ET-1-triggered reduction in SO$_2$ generation in VSMCs (Figure 4).

A previous study showed that H$_2$S acting as a gasotransmitter can inhibit the proliferation of vascular smooth muscle cells [38–40]. Some research reported that SO$_2$ could inhibit the proliferation and migration of myocardial fibroblasts [41]. In a study of hypoxia-induced pulmonary arteriolar remodeling, it was found that SO$_2$ significantly attenuated the interstitial thickening and prominent media hypertrophy of pulmonary arteries [42]. Therefore, we detected whether SO$_2$ is involved in the excessive proliferation and migration of vascular smooth muscle cells. Our research provides evidence of the interactions between peptides and gasotransmitters, which will help in
the understanding of the mechanisms by which vascular regulation by vasoactive small molecules depends on the integrated effects of these molecules as a complex network. These results are also significant for understanding the pathogenesis of vascular injury diseases, further deepening the significance of endogenous SO$_2$ in vascular injury diseases mainly characterized by smooth muscle cell proliferation and migration. However, in the future, further studies are needed to explore the molecular mechanism for the ROS-induced reduction in AAT activity and its significance in animal models.

5. Conclusion

The present study indicated that ET-1 downregulated the endogenous SO$_2$/AAT pathway, which is involved in the formation of proliferation and migration of VSMCs. The excessive ROS production mediated the ET-1-induced reduction of SO$_2$/AAT pathway. The above findings would be of great value in the understanding of the role of the endogenous SO$_2$/AAT pathway in the mechanisms for vascular diseases.

Data Availability

The data used to support the findings of this study are available from the corresponding authors upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

XT and QZ carried out the experimental work. XT and SC wrote the paper. CT, YS, JD, and HJ designed and supervised the experiments. JD, QZ, HJ, YH, and SC revised the primary manuscript. JD, YH, CT, and HJ were responsible for the quality control and analysis. XT, YS, and YH participated in the data analysis. All authors approved the final version of the manuscript. Xiaoyu Tian and Qingyou Zhang contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (81770278, 81622004, and 81770422), Natural Science Foundation of Beijing (7171010, 7182168, and 7191012), and National Youth Top-Notch Talent Support Program.

References

[1] S. S. Chen, C. S. Tang, H. F. Jin, and J. B. du, “Sulfur dioxide acts as a novel endogenous gaseous signaling molecule in the cardiovascular system,” Chinese Medical Journal, vol. 124, no. 12, pp. 1901–1905, 2011.

[2] A. Harvey, A. C. Montezano, R. A. Lopes, F. Rios, and R. M. Touyz, “Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications,” The Canadian Journal of Cardiology, vol. 32, no. 5, pp. 659–668, 2016.

[3] M. Yanagisawa, H. Kurihara, S. Kimura et al., “A novel potent vasoconstrictor peptide produced by vascular endothelial cells,” Nature, vol. 332, no. 6163, pp. 411–415, 1988.

[4] V. Nadeau, F. Potus, O. Boucherat et al., “Dual ET$_A$/ET$_B$ blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension,” Palm Circ, vol. 8, no. 1, p. 204589321741429, 2018.

[5] E. L. Schiffrin, “Vascular endothelin in hypertension,” Vascular Pharmacology, vol. 43, no. 1, pp. 19–29, 2005.

[6] J. J. Maguire and A. P. Davenport, "Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease," British Journal of Pharmacology, vol. 125, no. 2, pp. 238–240, 1998.

[7] S. Liu, R. D. Brook, W. Huang et al., “Extreme levels of ambient air pollution adversely impact cardiac and central aortic hemodynamics: the AIRCMD-China study," Journal of the American Society of Hypertension, vol. 11, no. 11, pp. 754–761.e3, 2017.

[8] O. W. Griffith, “Cysteinesulfinate metabolism altered partitioning during transamination and decarboxylation following administration of beta-methyleaspartate,” The Journal of Biological Chemistry, vol. 258, no. 3, pp. 1591–1598, 1983.

[9] S. X. Du, H. F. Jin, D. F. Bu et al., “Endogenously generated sulfur dioxide and its vasorelaxant effect in rats,” Acta Pharmacologica Sinica, vol. 29, no. 8, pp. 923–930, 2008.

[10] X. Zhao, H. F. Jin, C. S. Tang, and J. B. Du, “Effect of sulfur dioxide on vascular collagen remodeling in spontaneously hypertensive rats,” Zhonghua Er Ke Za Zhi, vol. 46, no. 12, pp. 905–908, 2008.

[11] W. Lan, H. P. Zhang, Y. Wang, M. Jiang, Q. Li, and D. An, “Antihypertensive effect of piperitene oxide on spontaneously hypertensive rat by regulating calcium balance and reducing endothelin-1 secretion,” Bangladesh Journal of Pharmacology, vol. 12, no. 3, pp. 341–347, 2017.

[12] Y. Sun, Y. Tian, M. Prabha et al., “Effects of sulfur dioxide on hypoxic pulmonary vascular structural remodeling,” Laboratory Investigation, vol. 90, no. 1, pp. 68–82, 2010.

[13] W. Li, C. Tang, H. Jin, and J. Du, “Regulatory effects of sulfur dioxide on the development of atherosclerotic lesions and vascular hydrogen sulfide in atherosclerotic rats,” Atherosclerosis, vol. 215, no. 2, pp. 323–330, 2011.

[14] M. W. Li, M. O. R. Mian, T. Barhoumi et al., “Endothelin-1 overexpression exacerbates atherosclerosis and induces aortic aneurysms in apolipoprotein E knockout mice,” Atherosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 10, pp. 2306–2315, 2013.

[15] J. M. McCord, “The evolution of free radicals and oxidative stress,” The American Journal of Medicine, vol. 108, no. 8, pp. 652–659, 2000.

[16] R. Ray and A. M. Shah, “NADPH oxidase and endothelial cell function,” Clinical Science, vol. 109, no. 3, pp. 217–226, 2005.

[17] K. K. Griendling, D. Sorescu, and M. Ushio-Fukai, “NAD(P)H oxidase: role in cardiovascular biology and disease,” Circulation Research, vol. 86, no. 5, pp. 494–501, 2000.

[18] A. Taleb, K. A. Ahmad, A. U. Ihsan et al., “Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases,” Biomedicine & Pharmacotherapy, vol. 102, pp. 689–698, 2018.

[19] S. M. Black, S. Kumar, D. Wiseman et al., “Pediatric pulmonary hypertension: roles of endothelin-1 and nitric oxide,”
Clinical Hemorheology and Microcirculation, vol. 37, no. 1-2, pp. 111–120, 2007.

[20] L. A. Brennan, R. H. Steinhorn, S. Wedgwood et al., “Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase,” Circulation Research, vol. 92, no. 6, pp. 683–691, 2003.

[21] B. M. Babior, “Phagocytes and oxidative stress,” The American Journal of Medicine, vol. 109, no. 1, pp. 33–44, 2000.

[22] J. Chi, L. Meng, S. Pan et al., “Primary culture of rat aortic vascular smooth muscle cells: a new method,” Medical Science Monitor, vol. 23, pp. 4014–4020, 2017.

[23] R. M. Touyz, G. Yao, E. Amiri, and E. L. Schiffrin, “Angiotensin II and endothelin-1 regulate MAP kinases through different redox-dependent mechanisms in human vascular smooth muscle cells,” Journal of Hypertension, vol. 22, no. 6, pp. 1141–1149, 2004.

[24] J. Fei, C. Viedt, U. Soto, C. Elsing, L. Jahn, and J. Kreuzer, “Endothelin-1 and smooth muscle cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 20, no. 5, pp. 1244–1249, 2000.

[25] M. Yoshizumi, S. Kim, S. Kagami et al., “Effect of endothelin-1 (1-31) on extracellular signal-regulated kinase and proliferation of human coronary artery smooth muscle cells,” British Journal of Pharmacology, vol. 125, no. 5, pp. 1019–1027, 1998.

[26] C. Wang, J. Liu, F. Guo, Y. Ji, and N. Liu, “Endothelin-1 induces the expression of C-reactive protein in rat vascular smooth muscle cells,” Biochemical and Biophysical Research Communications, vol. 389, no. 3, pp. 537–542, 2009.

[27] Y. Huang, Z. Shen, Q. Chen et al., “Endogenous sulfur dioxide alleviates collagen remodeling via inhibiting TGF-β/Smad pathway in vascular smooth muscle cells,” Scientific Reports, vol. 6, no. 1, 2016.

[28] A. L. Levonen, E. Vähäkangas, J. K. Koponen, and S. Ylä-Herttuala, “Antioxidant gene therapy for cardiovascular disease: current status and future perspectives,” Circulation, vol. 117, no. 16, pp. 2142–2150, 2008.

[29] F. P. Xu, M. S. Chen, Y. Z. Wang et al., “Leptin induces hypertrophy via endothelin-1-reactive oxygen species pathway in cultured neonatal rat cardiomyocytes,” Circulation, vol. 110, no. 10, pp. 1269–1275, 2004.

[30] S. Wedgwood, R. W. Dettman, and S. M. Black, “ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species,” American Journal of Physiology. Lung Cellular and Molecular Physiology, vol. 281, no. 5, pp. L1058–L1067, 2001.

[31] G. B. Dao and A. K. Srivastava, “Reactive oxygen species mediate endothelin-1-induced activation of ERK1/2, PKB, and Pyk2 signaling, as well as protein synthesis, in vascular smooth muscle cells,” Free Radical Biology & Medicine, vol. 37, no. 2, pp. 208–215, 2004.

[32] A. C. Montezano, D. Burger, T. M. Paravincini et al., “Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, Rac-1-independent pathways in human endothelial cells,” Circulation Research, vol. 106, no. 8, pp. 1363–1373, 2010.

[33] E. C. Viel, K. Benkirane, D. Javeshghani, R. M. Touyz, and E. L. Schiffrin, “Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats,” American Journal of Physiology Heart and Circulatory Physiology, vol. 295, no. 1, pp. H281–H288, 2008.

[34] S. Wedgwood and S. M. Black, “Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 288, no. 3, pp. L480–L487, 2005.

[35] N. L. Jernigan, B. R. Walker, and T. C. Resta, “Endothelium-derived reactive oxygen species and endothelin-1 attenuate NO-dependent pulmonary vasodilation following chronic hypoxia,” American Journal of Physiology Lung Cellular and Molecular Physiology, vol. 287, no. 4, pp. L801–L808, 2004.

[36] C. H. Chen, T. H. Cheng, H. Lin et al., “Reactive oxygen species generation is involved in epidermal growth factor receptor transactivation through the transient oxidization of Src homology 2-containing tyrosine phosphatase in endothelin-1 signaling pathway in rat cardiac fibroblasts,” Molecular Pharmacology, vol. 69, no. 4, pp. 1347–1355, 2006.

[37] F. Dong, X. Zhang, L. E. Wold, Q. Ren, Z. Zhang, and J. Ren, “Endothelin-1 enhances oxidative stress, cell proliferation and reduces apoptosis in human umbilical vein endothelial cells: role of ETB receptor, NADPH oxidase and caveolin-1,” British Journal of Pharmacology, vol. 145, no. 3, pp. 323–333, 2005.

[38] K. Ling, A. Xu, Y. Chen, X. Chen, Y. Li, and W. Wang, “Protective effect of a hydrogen sulfide donor on balloon injury-induced restenosis via the Nrf2/HIF-1α signaling pathway,” International Journal of Molecular Medicine, vol. 43, no. 3, pp. 1299–1310, 2019.

[39] T. Shuang, M. Fu, G. Yang, L. Wu, and R. Wang, “The interaction of IGF-1/IGF-1R and hydrogen sulfide on the proliferation of mouse primary vascular smooth muscle cells,” Biochemical Pharmacology, vol. 149, pp. 143–152, 2018.

[40] A. Sun, Y. Wang, J. Liu et al., “Exogenous H2S modulates mitochondrial fusion-fission to inhibit vascular smooth muscle cell proliferation in a hyperglycemic state,” Cell & Bioscience, vol. 6, no. 1, 2016.

[41] L. L. Zhang, J. B. du, C. S. Tang, H. F. Jin, and Y. Q. Huang, “Inhibitory effects of sulfur dioxide on rat myocardial fibroblast proliferation and migration,” Chinese Medical Journal, vol. 131, no. 14, pp. 1715–1723, 2018.

[42] L. Luo, X. Hong, B. Diao, S. Chen, and M. Hei, “Sulfur dioxide attenuates hypoxia-induced pulmonary arterial remodeling via Dkk1/Wnt signaling pathway,” Biomedicine & Pharmacotherapy, vol. 106, pp. 692–698, 2018.